Skip to main content

OXPAT Antibody [FITC]

Novus Biologicals, part of Bio-Techne | Catalog # NB110-60509F

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NB110-60509F

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Porcine, Bovine

Predicted:

Sheep (94%). Backed by our 100% Guarantee.

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Simple Western, Western Blot

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Summary for OXPAT Antibody [FITC]

Immunogen

A synthetic peptide made to a region of the human OXPAT protein, within residues 300-400. [UniProt# Q00G26]

Reactivity Notes

Porcine reactivity reported in scientific literature (PMID: 29094660). Immunogen displays the following percentage of sequence identity for non-tested species: sheep (94%), rat (84%).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for OXPAT Antibody [FITC]

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Frozen

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.

Simple Western

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: OXPAT

OXPAT (PLIN5/Perilipin 5) is a novel PAT-1 (Perilipin, ADRP and TIP47) that binds to lipid droplets (LDs) and protects them from lipolytic degradation. The tissue distribution of PAT-1 proteins differs considerably, however, all of them are involved in accumulation and metabolism of lipids in LDs. OXPAT covers LDs in the cytosol and its expression is highest in tissues with a high fat-oxidative capacity, such as heart, oxidative (type I) skeletal muscles and brown adipose tissue wherein the OXPAT contents parallel the LD content. OXPAT overexpression in OP-9 and COS-7 cells increased cellular triglyceride storage in parallel with increases in fatty acid oxidation and induction of gene expression of mitochondrial enzymes involved in oxidative metabolism. OXPAT has the potential of modulating the interaction of the major triacylglycerol lipase ATGL with LD as well as with its co-factor CGI-58 in a well control manner to regulate LD lipolysis. OXPAT expression is up-regulated by PPARalpha, and this regulation appears to be part of an expression program that shifts the metabolism of cells from fatty acid storage to oxidation.

Alternate Names

lipid storage droplet protein 5, LSDA5, LSDP5, MLDP, OXPAT, perilipin 5, perilipin-5

Gene Symbol

PLIN5

Additional OXPAT Products

Product Documents for OXPAT Antibody [FITC]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for OXPAT Antibody [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...